AU2017220012B2 - Nucleic acid carriers and therapeutic methods of use - Google Patents

Nucleic acid carriers and therapeutic methods of use Download PDF

Info

Publication number
AU2017220012B2
AU2017220012B2 AU2017220012A AU2017220012A AU2017220012B2 AU 2017220012 B2 AU2017220012 B2 AU 2017220012B2 AU 2017220012 A AU2017220012 A AU 2017220012A AU 2017220012 A AU2017220012 A AU 2017220012A AU 2017220012 B2 AU2017220012 B2 AU 2017220012B2
Authority
AU
Australia
Prior art keywords
antibody
targeting agent
fragment
directed
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017220012A
Other languages
English (en)
Other versions
AU2017220012A1 (en
Inventor
Lori Getts
Robert C. Getts
James M. Kadushin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Code Biotherapeutics Inc
Original Assignee
Code Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Code Biotherapeutics Inc filed Critical Code Biotherapeutics Inc
Publication of AU2017220012A1 publication Critical patent/AU2017220012A1/en
Priority to AU2024202345A priority Critical patent/AU2024202345A1/en
Application granted granted Critical
Publication of AU2017220012B2 publication Critical patent/AU2017220012B2/en
Assigned to CODE BIOTHERAPEUTICS, INC. reassignment CODE BIOTHERAPEUTICS, INC. Request for Assignment Assignors: GENISPHERE LLC
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A61K47/6885—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy the conjugate or the polymer being a starburst, a dendrimer, a cascade
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
AU2017220012A 2016-02-19 2017-02-17 Nucleic acid carriers and therapeutic methods of use Active AU2017220012B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024202345A AU2024202345A1 (en) 2016-02-19 2024-04-11 Nucleic acid carriers and therapeutic methods of use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662297194P 2016-02-19 2016-02-19
US62/297,194 2016-02-19
PCT/US2017/018323 WO2017143156A1 (en) 2016-02-19 2017-02-17 Nucleic acid carriers and therapeutic methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024202345A Division AU2024202345A1 (en) 2016-02-19 2024-04-11 Nucleic acid carriers and therapeutic methods of use

Publications (2)

Publication Number Publication Date
AU2017220012A1 AU2017220012A1 (en) 2018-08-16
AU2017220012B2 true AU2017220012B2 (en) 2024-05-02

Family

ID=59625528

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017220012A Active AU2017220012B2 (en) 2016-02-19 2017-02-17 Nucleic acid carriers and therapeutic methods of use
AU2024202345A Pending AU2024202345A1 (en) 2016-02-19 2024-04-11 Nucleic acid carriers and therapeutic methods of use

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024202345A Pending AU2024202345A1 (en) 2016-02-19 2024-04-11 Nucleic acid carriers and therapeutic methods of use

Country Status (6)

Country Link
US (2) US12338435B2 (enExample)
EP (1) EP3416671A4 (enExample)
JP (2) JP7366541B2 (enExample)
AU (2) AU2017220012B2 (enExample)
IL (1) IL260983B (enExample)
WO (1) WO2017143156A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3416691A4 (en) * 2016-02-19 2020-02-26 Genisphere, LLC SUPPORTS OF NUCLEIC ACIDS AND THEIR THERAPEUTIC METHODS OF USE
JP7366541B2 (ja) 2016-02-19 2023-10-23 コード バイオセラピューティクス インコーポレイテッド 核酸キャリア及び治療上の使用方法
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
CN108866635B (zh) * 2017-05-09 2021-11-26 安升（上海）医药科技有限公司 多特异性蛋白药物及其文库、以及制备方法和应用
US20190269728A1 (en) 2018-03-02 2019-09-05 Sixfold Bioscience Ltd. Compositions for delivery of cargo to cells
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US20210308273A1 (en) 2018-08-02 2021-10-07 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
JP2021533200A (ja) 2018-08-02 2021-12-02 ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. 顔面・肩甲・上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用
CA3112793A1 (en) * 2018-09-14 2020-03-19 Northwestern University Programming protein polymerization with dna
CN111196855B (zh) * 2018-11-19 2022-11-15 三生国健药业（上海）股份有限公司 抗egfr/pd-1双特异性抗体
AU2020329466B2 (en) * 2019-08-12 2024-08-01 Abl Bio Inc. Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof
US20230183746A1 (en) 2019-08-30 2023-06-15 Sixfold Bioscience Ltd. Compositions for transfer of cargo to cells
CN116249547B (zh) 2019-11-04 2025-11-14 代码生物疗法公司 脑特异性血管生成抑制剂1(bai1)抗体及其用途
EP4143316A2 (en) 2020-04-27 2023-03-08 Sixfold Bioscience Ltd. Compositions containing nucleic acid nanoparticles with modular functionality
CN115177740A (zh) * 2021-04-01 2022-10-14 安升（上海）医药科技有限公司 核酸自组装介导的adc药物的构建方法及应用
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP4366784A1 (en) 2021-07-09 2024-05-15 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11648318B2 (en) 2021-07-09 2023-05-16 Dyne Therapeutics, Inc. Anti-transferrin receptor (TFR) antibody and uses thereof
KR20250004770A (ko) 2022-04-15 2025-01-08 다인 세라퓨틱스, 인크. 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120122800A1 (en) * 2008-08-08 2012-05-17 Genisphere, LLC Hatfield, Pennsylvania Long-Acting DNA Dendrimers and Methods Thereof

Family Cites Families (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3641235A (en) 1968-11-01 1972-02-08 Miles Lab Immunological reagent and process for making same
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3966897A (en) 1973-04-02 1976-06-29 Marine Colloids, Inc. Medium for use in bioassay and method of using same
US3959078A (en) 1973-05-18 1976-05-25 Midwest Research Institute Enzyme immobilization with a thermochemical-photochemical bifunctional agent
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
SE388694B (sv) 1975-01-27 1976-10-11 Kabi Ab Sett att pavisa ett antigen exv i prov av kroppvetskor, med utnyttjande av till porost berarmaterial bundna eller adsorberande antikroppar
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
IL52322A (en) 1976-06-18 1980-10-26 Alfa Laval Ab Method of making reagent test device and device made accorording to this method
US4094647A (en) 1976-07-02 1978-06-13 Thyroid Diagnostics, Inc. Test device
US4196281A (en) 1976-10-20 1980-04-01 Regents Of The University Of California Psoralens
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4299916A (en) 1979-12-26 1981-11-10 Syva Company Preferential signal production on a surface in immunoassays
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4347312A (en) 1980-03-20 1982-08-31 Research Triangle Institute Detection of antibiotics in milk
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4425438A (en) 1981-03-13 1984-01-10 Bauman David S Assay method and device
US5141875A (en) 1982-01-08 1992-08-25 Environmental Diagnostics, Inc. Rotary fluid manipulator
US5073484A (en) 1982-03-09 1991-12-17 Bio-Metric Systems, Inc. Quantitative analysis apparatus and method
DE3327642A1 (de) 1983-07-30 1985-02-14 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur bestimmung eines partners einer immunreaktion sowie reagens zur durchfuehrung dieses verfahrens
EP0149168B1 (en) 1983-12-19 1991-04-24 Daiichi Pure Chemicals Co. Ltd. Immunoassay
US4695554A (en) 1984-02-14 1987-09-22 Becton Dickinson And Company Sac or liposome containing dye (sulforhodamine) for immunoassay
US4703017C1 (en) 1984-02-14 2001-12-04 Becton Dickinson Co Solid phase assay with visual readout
US4743560A (en) 1984-03-26 1988-05-10 Becton Dickinson And Company Solid phase assay
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
AU602694B2 (en) 1986-06-09 1990-10-25 Ortho Diagnostic Systems Inc. Improved colloidal gold membrane assay
US5514602A (en) 1986-06-09 1996-05-07 Ortho Diagnostic Systems, Inc. Method of producing a metal sol reagent containing colloidal metal particles
US5175270A (en) 1986-09-10 1992-12-29 Polyprobe, Inc. Reagents for detecting and assaying nucleic acid sequences
US4960691A (en) 1986-09-29 1990-10-02 Abbott Laboratories Chromatographic test strip for determining ligands or receptors
USRE38430E1 (en) 1987-03-27 2004-02-17 Becton, Dickinson And Company Solid phase chromatographic immunoassay
CA1303983C (en) 1987-03-27 1992-06-23 Robert W. Rosenstein Solid phase assay
US4857453A (en) 1987-04-07 1989-08-15 Syntex (U.S.A.) Inc. Immunoassay device
ES2150428T3 (es) 1987-04-27 2000-12-01 Unilever Nv Ensayos de union especifica.
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
US4956302A (en) 1987-09-11 1990-09-11 Abbott Laboratories Lateral flow chromatographic binding assay device
US5275785A (en) 1987-10-30 1994-01-04 Unilever Patent Holdings B.V. Test device for detecting an analyte in a liquid sample
ES2050697T3 (es) 1987-12-21 1994-06-01 Abbott Lab Metodos y dispositivos de ensayo de fijacion cromatografico.
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US6352862B1 (en) 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
ATE118824T1 (de) 1989-03-10 1995-03-15 Amoco Corp Immobilisierte oligonukleotidsonden und ihre verwendungen.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5075078A (en) 1989-10-05 1991-12-24 Abbott Laboratories Self-performing immunochromatographic device
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
KR910014706A (ko) 1990-01-10 1991-08-31 원본미기재 세척이 필요없는 개량된 이뮤노어세이(immunoassay)장치
US6395492B1 (en) 1990-01-11 2002-05-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
DE69123979T2 (de) 1990-10-12 1997-04-30 Max Planck Gesellschaft Abgeänderte ribozyme
US5998220A (en) 1991-05-29 1999-12-07 Beckman Coulter, Inc. Opposable-element assay devices, kits, and methods employing them
JP3267613B2 (ja) 1991-05-30 2002-03-18 アボツト・ラボラトリーズ イオン捕獲結合アッセイにおける非特異的結合遮断薬を含む試薬
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
FI92882C (fi) 1992-12-29 1995-01-10 Medix Biochemica Ab Oy Kertakäyttöinen testiliuska ja menetelmä sen valmistamiseksi
DE69433036T2 (de) 1993-09-03 2004-05-27 Isis Pharmaceuticals, Inc., Carlsbad Aminoderivatisierte nukleoside und oligonukleoside
PT653639E (pt) 1993-11-12 2000-06-30 Unilever Nv Equipamentos analiticos e metodos para a sua utilizacao
PL182237B1 (pl) 1994-03-07 2001-11-30 Dow Chemical Co Sposób przeprowadzania transfekcji komórek i osiagniecia biodostepnosci materialu genetycznego in vitro i ex vivo PL PL
GB9419267D0 (en) 1994-09-23 1994-11-09 Unilever Plc Assay devices
GB9505425D0 (en) 1995-03-17 1995-05-03 Unilever Plc Assay devices
US5653979A (en) 1995-03-30 1997-08-05 Trustees Of The University Of Pennsylvania Immunotargeting of plasminogen activators to the pulmonary endothelium
US20010051350A1 (en) 1995-05-02 2001-12-13 Albert Nazareth Diagnostic detection device and method
SE9501671D0 (sv) 1995-05-05 1995-05-05 Pharmacia Ab Method and composition for prevention of posterior capsule opacification
AU6720096A (en) 1995-08-09 1997-03-05 Quidel Corporation Test strip and method for one step lateral flow assay
US6072043A (en) 1996-06-04 2000-06-06 Polyprobe, Inc. Optimally fluorescent oligonucleotides
US5846737A (en) 1996-07-26 1998-12-08 Molecular Probes, Inc. Conjugates of sulforhodamine fluorophores with enhanced fluorescence
US6117631A (en) 1996-10-29 2000-09-12 Polyprobe, Inc. Detection of antigens via oligonucleotide antibody conjugates
GB2322192B (en) 1997-02-14 2001-01-31 Unilever Plc Assay devices
US6924153B1 (en) 1997-03-06 2005-08-02 Quidel Corporation Quantitative lateral flow assays and devices
WO1999005284A1 (fr) 1997-07-25 1999-02-04 Agene Research Institute, Co., Ltd. GENE HUMAIN RecQ4 CODANT HELICASE
EP1005573B1 (en) * 1997-07-29 2006-05-24 Polyprobe, Inc. Dendritic nucleic acids exhibiting maximal self-assembly
WO1999040438A1 (en) 1998-02-03 1999-08-12 Synbiotics Corporation Device and method to detect immunoprotective antibody titers
AU753303B2 (en) 1998-03-10 2002-10-17 Trustees Of The University Of Pennsylvania, The Enhancement of intracellular delivery and tissue targeting of drugs and genes
US6287765B1 (en) 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
US7041287B2 (en) 1998-05-21 2006-05-09 Trustees Of The University Of Pennsylvania Compositions and methods for selective dissolution of nascent intravascular blood clots
AU762670B2 (en) 1998-05-21 2003-07-03 Trustees Of The University Of Pennsylvania, The Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots
ATE310536T1 (de) 1998-08-04 2005-12-15 Univ Pennsylvania Zielrichtung und verlängerte assoziation von wirkstoffen an die luminale oberfläche der pulmonaren vaskularen endothelzellen
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
US7674466B2 (en) 1999-08-05 2010-03-09 The Trustees Of The University Of Pennsylvania Targeting and prolonging association of drugs to the luminal surface of the pulmonary vascular endothelial cells using antibodies that bind to ICAM-1
US6822086B1 (en) 1999-08-09 2004-11-23 The General Hospital Corporation Drug-carrier complexes and methods of use thereof
US6773928B1 (en) 1999-09-22 2004-08-10 The United States Of America As Represented By The Secretary Of The Army Compositions and methods for enhancing bioassay performance
US6180357B1 (en) 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US6506600B2 (en) 2000-03-22 2003-01-14 University Of Arkansas Secreting products from skin by adeno-associated virus (AAV) gene transfer
US20010036460A1 (en) 2000-04-06 2001-11-01 Sawicki Janet A. Targeted death cancer cells
EP1282449A2 (en) 2000-05-12 2003-02-12 The Regents Of The University Of California Treatment of human papillomavirus (hpv)-infected cells
ATE375516T1 (de) 2000-06-12 2007-10-15 Fujirebio Kk Immuntest zur messung des humanen c-peptides sowie reagenzienkit hierfür
ATE388402T1 (de) 2000-07-19 2008-03-15 Genisphere Inc Verfahren zur erkennung und zum assay von nukleinsäuresequenzen
US6770487B2 (en) 2001-05-01 2004-08-03 Ischemia Technologies, Inc. Bar code readable diagnostic strip test
US20070173473A1 (en) 2001-05-18 2007-07-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
AU2002345847B2 (en) 2001-06-21 2008-05-29 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
GR1003966B (el) 2001-10-16 2002-08-06 Εμβαπτιζομενος χαρτης αποξηραμενων αντιδραστηριων και μεθοδος για την ανιχνευση η και προσδιορισμο ειδικων αλληλουχιων νουκλεικων οξεων
EP1461606A4 (en) 2001-12-05 2005-06-29 Univ Washington MICROFLUIDIC DEVICE AND SURFACE DECORATION PROCESS FOR SOLID PHASE AFFINITY BINDING ASSAYS
US20040023248A1 (en) 2001-12-07 2004-02-05 Whitehead Institiute For Biomedical Research Methods and reagents for improving nucleic acid detection
AU2002357932A1 (en) 2001-12-18 2003-06-30 Whitehead Institute For Biomedical Research Fusion partner cells and uses thereof
US7175992B2 (en) 2002-04-10 2007-02-13 Response Biomedical Corporation Sensitive immunochromatographic assay
EP1530581A4 (en) 2002-06-12 2006-08-30 Datascope Investment Corp POLYMERIC MARKING MOLECULES
EP2392345A3 (en) 2002-07-18 2012-03-07 Cytos Biotechnology AG Hapten-carrier conjugates comprising virus like particles and uses thereof
AU2003269557A1 (en) 2002-10-18 2004-05-04 Lg Life Sciences Ltd. Gene families associated with cancers
MXPA05004588A (es) 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
DK2284266T3 (da) 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
WO2004062602A2 (en) 2003-01-09 2004-07-29 Arizeke Pharmaceuticals Inc. Compositions and methods for targeted biological delivery of molecular carriers
BRPI0407446A (pt) 2003-02-13 2006-01-31 Pharmacia Corp Anticorpos para c-met para o tratamento de cânceres
US20040220084A1 (en) 2003-05-02 2004-11-04 Jasbir Sandhu Methods for nucleic acid delivery
CA2525367A1 (en) 2003-05-09 2004-11-25 The Trustees Of The University Of Pennsylvania Use of citrate lyase inhibitors and tricarboxylate transporter inhibitors in the treatment of cancer
US7317532B2 (en) 2003-06-04 2008-01-08 Inverness Medical Switzerland Gmbh Flow sensing for determination of assay results
US7223544B2 (en) 2003-06-27 2007-05-29 Cornell Research Foundation, Inc. Nucleic acid-engineered materials
US7445906B2 (en) 2003-06-30 2008-11-04 East Carolina University Method of detecting cancer using delta-catenin
US7238538B2 (en) 2003-09-19 2007-07-03 Freitag Helmut E Chromatographic assay device and methods
US20060228404A1 (en) 2004-03-04 2006-10-12 Anderson Daniel G Compositions and methods for treatment of hypertrophic tissues
US20050215507A1 (en) 2004-03-04 2005-09-29 Massachusetts Institute Of Technology Therapeutic anti-cancer DNA
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
WO2005113571A2 (en) 2004-05-13 2005-12-01 The University Of North Carolina At Chapel Hill Methods for the delivery of oligomeric compounds
US20060040879A1 (en) 2004-08-21 2006-02-23 Kosak Kenneth M Chloroquine coupled nucleic acids and methods for their synthesis
US8445293B2 (en) 2005-02-09 2013-05-21 Rapid Pathogen Screening, Inc. Method to increase specificity and/or accuracy of lateral flow immunoassays
WO2006098804A2 (en) 2005-03-11 2006-09-21 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
US7189522B2 (en) 2005-03-11 2007-03-13 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
US8067572B2 (en) 2005-05-25 2011-11-29 The University Of York Hybrid interfering RNA
EP1893292A2 (en) 2005-05-26 2008-03-05 Thomas Jefferson University Method to treat and prevent posterior capsule opacification
US20070015166A1 (en) 2005-07-14 2007-01-18 Nilsen Thor W Lateral flow methods and devices for detection of nucleic acid binding proteins
US20100136614A1 (en) 2005-10-18 2010-06-03 Dan Luo Dendrimer-like modular delivery vector
WO2008039206A2 (en) 2005-10-05 2008-04-03 The Trustees Of The University Of Pennsylvania Fusion proteins for inhibition and dissolution of coagulation
US20120003727A1 (en) 2006-03-10 2012-01-05 Javanbakhsh Esfandiari Immunoassay Device for Detecting Antibodies and Antigens
US20070225213A1 (en) 2006-03-23 2007-09-27 Kosak Matthew K Nucleic acid carriers for delivery of therapeutic agents
JP2008195613A (ja) 2006-12-19 2008-08-28 Nissei Bio Kk マイクロ微粒子製剤および医薬組成物
DK2308514T3 (da) 2007-03-23 2013-09-02 To Bbb Holding B V Konjugater til målrettet lægemiddeltransport gennem blod-hjerne barrieren
US9217151B2 (en) * 2007-05-16 2015-12-22 California Institute Of Technology Versatile nucleic acid hairpin motif for programming biomolecular self-assembly pathways
WO2008147526A1 (en) 2007-05-23 2008-12-04 The Trustees Of The University Of Pennsylvania Targeted carriers for intracellular drug delivery
MX2010001194A (es) * 2007-07-31 2010-07-30 Univ Louisiana State Conjugado de polipeptido-acido nucleico para inmunoprofilaxis o inmunoterapia para desordenes neoplasicos o infecciones.
US9029524B2 (en) 2007-12-10 2015-05-12 California Institute Of Technology Signal activated RNA interference
BRPI0821417A2 (pt) 2007-12-26 2015-06-16 Biotest Ag Método para diminuir a adesão de células de estroma a células tumorais que expressam cd138 em células tumorais de um indivíduo em necessidade do mesmo
WO2009086552A1 (en) 2008-01-02 2009-07-09 The Trustees Of The University Of Pennsylvania Targeting recombinant therapeutics to circulating red blood cells
US20090297479A1 (en) 2008-03-28 2009-12-03 Kiyoshi Ariizumi Dc-hil conjugates for treatment of t-cell disorders
US20110160090A1 (en) 2008-05-05 2011-06-30 Los Alamos National Laboratory Nanocrystal-Based Lateral Flow Microarrays and Low-Voltage Signal Detection Systems
WO2010045518A1 (en) 2008-10-16 2010-04-22 The Trustees Of The University Of Pennsylvania Compositions containing thrombomodulin domains and uses thereof
WO2010065920A1 (en) 2008-12-04 2010-06-10 Lankenau Institute For Medical Research Compositions and methods for the treatment and prevention of lens fibrotic diseases
WO2010107960A1 (en) 2009-03-17 2010-09-23 Brody Jonathan R Methods for assessing the efficacy of gemcitabine or ara-c treatment of cancer using human antigen r levels
AU2010244428B2 (en) 2009-05-06 2015-01-29 Biotest Ag Uses of immunoconjugates targeting CD138
US20100323018A1 (en) 2009-06-17 2010-12-23 Massachusetts Institute Of Technology Branched DNA/RNA monomers and uses thereof
US20110206611A1 (en) 2010-02-24 2011-08-25 Genisphere, Llc DNA Dendrimers as Thermal Ablation Devices
US20130018086A1 (en) 2010-03-16 2013-01-17 Massachusette Institute Of Technology Sirnas targeting exon 10 of pyruvate kinase m2
JP4638555B1 (ja) 2010-09-08 2011-02-23 田中貴金属工業株式会社 核酸又は免疫クロマトグラフィー用試薬組成物、核酸又は免疫クロマトグラフィー測定方法及び核酸又は免疫クロマトグラフィー測定用キット
WO2012061402A2 (en) 2010-11-01 2012-05-10 Syracuse University System and method for delivery of dna-binding chemotherapy drugs using nanoparticles
US20140212503A1 (en) 2011-03-17 2014-07-31 Hyukjin Lee Delivery system
EP2998320B1 (en) 2011-04-19 2018-07-18 The United States of America, as represented by the Secretary, Department of Health and Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
WO2013134768A1 (en) 2012-03-09 2013-09-12 Lankenau Institute For Medical Research Compositions and methods for treating cancer
RU2644263C2 (ru) 2012-06-27 2018-02-08 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения селективных и мультиспецифических терапевтических молекул с заданными свойствами, включающих по меньшей мере две различные нацеливающие группировки, и их применения
US9651549B2 (en) 2012-07-13 2017-05-16 Genisphere, Llc Lateral flow assays using DNA dendrimers
EP2895211B1 (en) 2012-09-12 2017-10-18 Boston Scientific Scimed, Inc. Adhesive stent coating for anti-migration
HK1214628A1 (zh) 2012-11-05 2016-07-29 Pronai Therapeutics, Inc. 寡核苷酸癌症療法的給藥和施用
CN105073141A (zh) 2013-02-01 2015-11-18 詹尼斯费尔公司 用于将基因递送到细胞的功能化dna树状聚合物
EP2976109B1 (en) 2013-03-21 2018-07-25 Genisphere, LLC Cellular delivery of dna intercalating agents
MX376384B (es) 2013-11-27 2025-03-07 Zymeworks Bc Inc Construcciones de union a antigenos biespecificas dirigidas a her2.
GB201502645D0 (en) 2015-02-17 2015-04-01 Touchlight Genetics Ltd Method
EP3289084B1 (en) 2015-04-17 2020-09-16 Genisphere, LLC siRNA INHIBITION OF HUMAN ANTIGEN R EXPRESSION FOR TREATMENT OF CANCER
JP7366541B2 (ja) 2016-02-19 2023-10-23 コード バイオセラピューティクス インコーポレイテッド 核酸キャリア及び治療上の使用方法
EP3416691A4 (en) 2016-02-19 2020-02-26 Genisphere, LLC SUPPORTS OF NUCLEIC ACIDS AND THEIR THERAPEUTIC METHODS OF USE
CN116249547B (zh) * 2019-11-04 2025-11-14 代码生物疗法公司 脑特异性血管生成抑制剂1(bai1)抗体及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120122800A1 (en) * 2008-08-08 2012-05-17 Genisphere, LLC Hatfield, Pennsylvania Long-Acting DNA Dendrimers and Methods Thereof

Also Published As

Publication number Publication date
JP2019511474A (ja) 2019-04-25
AU2024202345A1 (en) 2024-05-02
US20210213138A1 (en) 2021-07-15
AU2017220012A1 (en) 2018-08-16
JP7366541B2 (ja) 2023-10-23
US12338435B2 (en) 2025-06-24
EP3416671A1 (en) 2018-12-26
JP2022050550A (ja) 2022-03-30
IL260983A (enExample) 2018-09-20
EP3416671A4 (en) 2019-10-30
US20230136794A1 (en) 2023-05-04
WO2017143156A1 (en) 2017-08-24
IL260983B (en) 2022-07-01

Similar Documents

Publication Publication Date Title
US20230136794A1 (en) Nucleic Acid Carriers And Therapeutic Methods Of Use
US20250049942A1 (en) Nucleic acid carriers and therapeutic methods of use
US11613609B2 (en) PLGA-modified polyethylenimine self-assembly nanotechnology for nucleic acid and drug delivery
US20240033376A1 (en) Systems and methods for nucleic acid expression in vivo
JP6596478B2 (ja) 免疫療法のためのｒｎａ製剤
US20200010795A1 (en) Engineered Cells And Methods Of Use
KR20210039376A (ko) 개인 맞춤형 암 백신
EP3777840B1 (en) Rna formulation for immunotherapy
WO2025235413A1 (en) Compositions targeting cancer antigens and methods of use thereof
JP2025538981A (ja) ＴＧＦ－β１ワクチン
WO2025213057A1 (en) Engineered major histocompatibility complex molecules and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)